ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Parabilis Medicines
38.37
+2.65
7.42%
成交量：
40.49萬
成交額：
1,526.52萬
市值：
47.58億
市盈率：
-1.64
高：
38.92
開：
36.19
低：
35.37
收：
35.72
52周最高：
41.49
52周最低：
24.51
股本：
1.24億
流通股本：
3,350.00萬
量比：
1.77
換手率：
1.21%
股息：
- -
股息率：
- -
每股收益(TTM):
-23.4458
每股收益(LYR):
-60.0402
淨資產收益率：
--
總資產收益率：
--
市淨率：
4.54
市盈率(LYR):
-0.64
資料載入中...
總覽
公司
新聞資訊
公告
Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員
投资观察
·
08/25
Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員
美股速递
·
08/25
Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年
美股速递
·
08/13
美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價
美股速递
·
07/06
美國研究綜述-東西銀行、第一公民銀行控股公司、UMB
路透中文
·
07/06
Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權
美股速递
·
06/12
異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開
行情直击
·
06/11
熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲
路透中文
·
06/11
異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%
异动解读
·
06/11
美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場 開盤後股價升逾44%
智通财经
·
06/11
癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購 最終募資7.45億美元
智通财经
·
06/10
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/PBLS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":38.37,"timestamp":1789576134259,"preClose":35.72,"halted":0,"volume":404878,"delay":0,"changeRate":0.07418812989921608,"floatShares":33500000,"shares":124000000,"eps":-23.44581,"marketStatus":"交易中","change":2.65,"latestTime":"09-16 12:29:01 EDT","open":36.19,"high":38.915,"low":35.3709,"amount":15265175.155943999,"amplitude":0.099219,"askPrice":38.66,"askSize":70,"bidPrice":38.32,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-23.44581,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":35.72,"preHourTrading":{"tag":"盘前","latestPrice":36.43,"preClose":35.72,"latestTime":"08:25 EDT","volume":8,"amount":287.75,"timestamp":1789561558266,"change":0.71,"changeRate":0.019877,"amplitude":0.055991},"postHourTrading":{"tag":"盘后","latestPrice":35.72,"preClose":35.72,"latestTime":"19:30 EDT","volume":2801,"amount":100037.6436,"timestamp":1789515006670,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.77189,"impliedVol":0.4704,"impliedVolPercentile":0.093},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","floatShares":33500000,"roa":"--","roe":"--","lyrEps":-60.040199,"volumeRatio":1.77189,"shares":124000000,"dividePrice":0,"high":38.915,"amplitude":0.099219,"preClose":35.72,"low":35.3709,"week52Low":24.51,"pbRate":"4.54","psRate":"32147.84","week52High":41.4899,"institutionHeld":0,"latestPrice":38.37,"committee":0.481481,"eps":-23.44581,"divideRate":0,"volume":404878,"delay":0,"ttmEps":-23.44581,"open":36.19,"prevYearClose":20,"prevWeekClose":36.88,"prevMonthClose":39.01,"prevQuarterClose":27.37,"fiveDayClose":38.76,"twentyDayClose":39.35,"sixtyDayClose":27.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBLS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PBLS","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBLS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBLS","date":"2026-09-15","current":-1.63654,"percent":0.538462,"low":-31.159897,"twenty":-28.671719,"median":-26.487161,"eighty":-23.423744,"high":-15.535256,"avg":-26.157708,"sd":2.915634,"marketCap":4466961958},"quantilePoints":[{"date":"2026-06-12","current":-23.423744,"twenty":-24.021896,"median":-23.423744,"eighty":-18.690651,"marketCap":3580998591},{"date":"2026-06-18","current":-21.681158,"twenty":-23.280127,"median":-22.147598,"eighty":-21.001488,"marketCap":3314593719},{"date":"2026-06-26","current":-21.956025,"twenty":-22.933884,"median":-22.426629,"eighty":-21.561216,"marketCap":3356615076},{"date":"2026-07-02","current":-23.122126,"twenty":-23.423744,"median":-22.77646,"eighty":-21.681158,"marketCap":3534887500},{"date":"2026-07-10","current":-25.287743,"twenty":-24.420664,"median":-22.938881,"eighty":-21.956025,"marketCap":3865964860},{"date":"2026-07-17","current":-24.204934,"twenty":-24.912925,"median":-23.706058,"eighty":-22.147598,"marketCap":3700426180},{"date":"2026-07-24","current":-27.328421,"twenty":-25.279414,"median":-24.204934,"eighty":-22.705661,"marketCap":4177941603},{"date":"2026-07-31","current":-26.886968,"twenty":-25.665893,"median":-24.321545,"eighty":-22.738979,"marketCap":4110452756},{"date":"2026-08-07","current":-29.635636,"twenty":-26.527142,"median":-24.625564,"eighty":-22.753971,"marketCap":4530666328},{"date":"2026-08-14","current":-29.710599,"twenty":-28.289622,"median":-24.912925,"eighty":-22.788954,"marketCap":4542126698},{"date":"2026-08-21","current":-28.671719,"twenty":-28.53843,"median":-25.283578,"eighty":-22.890572,"marketCap":4889445639},{"date":"2026-08-28","current":-28.461644,"twenty":-28.506557,"median":-25.662561,"eighty":-22.933884,"marketCap":4853620999},{"date":"2026-09-04","current":-29.519266,"twenty":-28.607972,"median":-26.20813,"eighty":-23.085477,"marketCap":5033979530},{"date":"2026-09-11","current":-26.310178,"twenty":-28.726773,"median":-26.487161,"eighty":-23.303097,"marketCap":4486727276},{"date":"2026-09-15","current":-26.194274,"twenty":-28.671719,"median":-26.487161,"eighty":-23.423744,"marketCap":4466961958}],"updateTime":1789576141549},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBLS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121669089","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1121669089","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121669089?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:04","pubTimestamp":1787655884,"startTime":"0","endTime":"0","summary":"马萨诸塞州剑桥，2026年8月25日——Parabilis Medicines今日正式宣布，Craig L. Tendler博士将加入公司董事会。Tendler博士的职业生涯亮点颇多。此前，他已担任Parabilis Medicines的科学顾问，此番履新后，他将同时肩负这两个重要角色。\"我们非常高兴欢迎Craig加入Parabilis董事会。在这个关键节点加入Parabilis董事会，我倍感欣喜。目前，Tendler博士还担任TuHURA Biosciences和Predicta Biosciences的董事会成员，并为多家生物技术公司提供科学顾问服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","LU1861214812.USD","BK4605","PBLS","LU1861219969.SGD","IE00BD6J9T35.USD","LU0348723411.USD","IE00BFMHRM44.USD","LU1720051108.HKD","BK4555","BK4588","LU2360107325.USD","BK4232","LU1861220033.SGD","LU1854103824.USD","BK4141","LU1978683503.SGD","ONG","ONX","BK4585","LU1983260115.SGD","TM","BK4512","03160","BK4099","BK4006","R","LU2357305700.SGD","LU1861215975.USD","LU0124384867.USD","ACP","BK4022","LU2298322129.HKD","COAL","LU1854104046.USD","LU0724618433.USD","BK4139","IE00BZ199S13.USD","LU1720051017.SGD","BK4604","LU1548497426.USD","ON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143247197","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1143247197","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143247197?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:01","pubTimestamp":1787655676,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，已正式任命在药物开发领域建树颇丰的Craig L. Tendler医学博士加入公司董事会。Tendler博士拥有数十年的行业经验，其职业生涯横跨多个治疗领域，并在推动创新疗法从早期研究走向商业化方面拥有卓越记录。此次人事任命，被视作公司强化战略领导力的关键一步，旨在加速其管线资产的推进与拓展。Parabilis Medicines方面表示，Tendler博士的深厚专业知识和广泛行业网络，将为公司在复杂多变的生物制药环境中导航提供重要支持。随着Tendler博士的加入，董事会将更加多元，决策视角亦更为丰富，为公司下一阶段的发展注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110375422","title":"Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1110375422","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110375422?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 19:07","pubTimestamp":1786619229,"startTime":"0","endTime":"0","summary":"Parabilis Medicines 在第二季度结束时，所持有的现金、现金等价物以及有价证券总额高达11亿美元。这笔充裕的资金储备，预计将足以支撑公司的运营活动，直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146739009","title":"美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1146739009","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146739009?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:39","pubTimestamp":1783337956,"startTime":"0","endTime":"0","summary":"美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649644013","title":"美國研究綜述-東西銀行、第一公民銀行控股公司、UMB","url":"https://stock-news.laohu8.com/highlight/detail?id=2649644013","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649644013?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 16:22","pubTimestamp":1783326173,"startTime":"0","endTime":"0","summary":"美国研究综述-东西银行、第一公民银行控股公司、UMB路透7月6日-周一，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括东西银行、第一公民银行控股公司和UMB金融公司。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4S4380GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","FTXH","PJP","BBH","REGN","ADP","BIIB","DLTR","AGMI","CCB","FCNCA","MEDI","NEMG","OZEM","UNHW","HBAN","XLV","ZTS","IHF","IBB","EKG","UMBF","OZK","FRBT","PFE","MRK","PBLS","CVS","SOC","GILD","UNHG","EROC","IHE","ZION","NEM","RGLD","CFR","UNH","PAWZ","DFNL","WTFC","CBSH","EWBC","AGNG","USB","QABA","JNJ","PNFP","FLG","IQV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189403882","title":"Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權","url":"https://stock-news.laohu8.com/highlight/detail?id=1189403882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189403882?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 04:06","pubTimestamp":1781208398,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，其规模扩大的首次公开募股（IPO）已正式完成。此次发行中，承销商全额行使了购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120727250","title":"異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開","url":"https://stock-news.laohu8.com/highlight/detail?id=1120727250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120727250?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 02:03","pubTimestamp":1781114598,"startTime":"0","endTime":"0","summary":"6月10日，Parabilis Medicines盘中上涨49.15%，报29.83美元/股，成交额1.01亿美元。消息面上，公司当日完成美股IPO并挂牌上市，发行价定为每股20美元，高于此前17-19美元的推介区间，IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股，募资约6.70亿美元；同时再生元制药以每股18美元认购约7500万美元股份，合计筹资近7.45亿美元。Parabilis Medicines是一家临床阶段生物制药公司，专注于开发用于癌症治疗的工程化肽疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478308","title":"熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478308","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478308?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:20","pubTimestamp":1781112027,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL4S42I1G5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0109394709.USD","LU1974910355.USD","BK4588","NUVL","LU2089984988.USD","LU0053666078.USD","LU0114720955.EUR","PBLS","LU0058720904.USD","LU0289739699.SGD","LU0889565916.HKD","LU2023250504.SGD","BK4585","LU0823434740.USD","LU2106854487.HKD","LU1917777945.USD","LU2362541273.HKD","LU0823416689.USD","LU2237438978.USD","LU0823434583.USD","LU2362540622.SGD","LU2468319806.SGD","BK4539","BK4139","LU0882574055.USD","LU0320765992.SGD","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104824154","title":"異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104824154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104824154?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:12","pubTimestamp":1781111553,"startTime":"0","endTime":"0","summary":"生物科技公司Parabilis Medicines 今日盘中股价大幅飙升66.75%，成为市场焦点。Parabilis Medicines成立于2015年，专注于开发针对多种癌症及罕见肿瘤的治疗方案，此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段，这增强了投资者对公司未来发展的信心。市场分析认为，尽管公司目前处于亏损状态，但其在癌症治疗领域的专业性和IPO带来的资金注入，为其后续的研发和商业化提供了关键支持，从而推动了股价的积极表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478833","title":"美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場 開盤後股價升逾44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478833?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，聚焦癌症治疗的美国生物科技公司Parabilis Medicines(PBLS.US)登陆美股市场，开盘股价走高，截至发稿，该股涨44.35%，报28.87美元。IPO价格为20美元。Parabilis成立于2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。公司拟将IPO募集资金用于推进其最领先候选药物zolucatetide进入更后期临床试验阶段。截至2025财年年末，Parabilis净亏损1.459亿美元，期末现金及现金等价物2,770万美元;前一财年净亏损为1.179亿美元，现金为4,730万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414058","title":"癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購 最終募資7.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642414058?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 11:30","pubTimestamp":1781062200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines完成了一项规模上调的美股IPO，发行价定在推介区间之上，叠加同步进行的私募配售，合计筹资近 7.45亿美元。在本次周二上调规模前，IPO认购需求已达可供股份数的约10倍。文件显示，截至 2025财年年末，Parabilis 净亏损 1.459亿美元，期末现金及现金等价物 2,770万美元;前一财年净亏损为 1.179亿美元，现金为 4,730万美元。Parabilis 成立于 2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}